Non-Hodgkin’s Lymphomas
Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Furhan Yunus(Mobile Infirmary), Leonard R. Prosnitz, Nancy L. Harris(World Resources Institute), Oliver W. Press(Fred Hutch Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Lubomir Sokol(Moffitt Cancer Center), Pierluigi Porcu(Thomas Jefferson University), Ranjana H. Advani(Stanford Medicine), Charalambos Andreadis(University of California, San Francisco), Steven M. Horwitz(Memorial Sloan Kettering Cancer Center), Richard T. Hoppe(Stanford Medicine), Mark Kaminski(Sheba Medical Center), Julie M. Vose(University of Nebraska Medical Center), Joachim Yahalom, Nashitha Reddy, Ann S. LaCasce(Otsuka (Japan)), Mitchell R. Smith, Tariq I. Mughal(Tufts University), Andres Forero, Youn H. Kim(Stanford University), Jon P. Gockerman, John C. Byrd, William G. Wierda(The University of Texas MD Anderson Cancer Center), Myron S. Czuczman(Roswell Park Comprehensive Cancer Center), Auyporn Nademanee, Martha Glenn(Huntsman Cancer Institute), Jeremy S. Abramson(Massachusetts General Hospital), Lode J. Swinnen(Johns Hopkins University), Leo I. Gordon(Northwestern University)
Cited by 329
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k